Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/15/2021 | $12.00 | Buy | HC Wainwright & Co. |
HC Wainwright & Co. initiated coverage of Virios Therapeutics with a rating of Buy and set a new price target of $12.00
SC 13D - Virios Therapeutics, Inc. (0001818844) (Subject)
SC 13G/A - Virios Therapeutics, Inc. (0001818844) (Subject)
SC 13G/A - Virios Therapeutics, Inc. (0001818844) (Subject)
Shares of CrowdStrike Holdings, Inc. (NASDAQ:CRWD) fell sharply during Monday’s session. Guggenheim analyst John Difucci downgraded the stock from Buy to Neutral, while BTIG analyst Gray Powell downgraded the stock from Buy to Neutral. CrowdStrike shares dipped over 11% on Friday after the company suffered a major outage impacting businesses around the world. Selective Insurance Group shares dipped 13.2% to $264.65 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) shares climbed 148% to $1.98 after the company announced new preclinical study results for its novel oral ketamine analog, Ketamir-2. CareMa
DEFA14A - Virios Therapeutics, Inc. (0001818844) (Filer)
8-K - Virios Therapeutics, Inc. (0001818844) (Filer)
10-Q - Virios Therapeutics, Inc. (0001818844) (Filer)
4 - Virios Therapeutics, Inc. (0001818844) (Issuer)
4 - Virios Therapeutics, Inc. (0001818844) (Issuer)
4 - Virios Therapeutics, Inc. (0001818844) (Issuer)
ATLANTA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM") and Long-COVID ("LC"), announced today that it will report second quarter 2024 financial results on Thursday, August 8, 2024 before the open of the financial markets. About Virios Therapeutics Virios Therapeutics (NASDAQ:VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia ("FM") and Long-CO
- Top-line results from the ongoing investigator-initiated Bateman Horne Center Long-COVID phase 2 featuring valacyclovir and celecoxib (IMC-2) expected in the second-half of 2024 - - Conference Call Today at 8:30 a.m. ET - ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM") and Long-COVID ("LC"), today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update. Key Highlights The BHC-202 3-arm study comparing two dose levels of the valacyc
ATLANTA, May 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM") and Long-COVID ("LC"), announced today that it will report first quarter 2024 financial results on Thursday, May 9, 2024 before the open of the financial markets. Management will also host a webcast and conference call on May 9, 2024 at 8:30 a.m. ET to discuss the results and provide a corporate update. The live and archived webcast of the call may be accessed on the Virios Therapeutics website under the Investors section: Events and
Strategic financing by an affiliate of CK Life Sciences Int'l., (Holdings) Inc., results in working capital of approximately $23 million to fund operations and advance Phase 2b Halneuron® development into 4Q25 Expanded pipeline includes a potential first-in-class non-opioid, NaV1.7 inhibition pain treatment, Halneuron®, currently in Phase 2b development for chemotherapy-induced neuropathic pain, with an expected interim readout 2H25Near-term catalyst with top-line results from the IMC-2 Long-COVID Phase 2a study expected in early 4Q24 Existing VIRI stockholders to be granted a contingent value right ("CVR") tied to potential milestone payments associated with any future corporate partneri
- Bateman Horne Center completed enrollment in its groundbreaking investigator-initiated Long-COVID phase 2a study featuring valacyclovir and celecoxib (IMC-2) - - Top-line results from the Bateman Horne Center's Long-COVID phase 2a study expected in October 2024, will provide key insights into final design of planned Phase 2b study - ATLANTA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM") and Long-COVID ("LC"), today announced financial results for the second quarter ended June 30, 2
ATLANTA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM") and Long-COVID ("LC"), announced today that it will report second quarter 2024 financial results on Thursday, August 8, 2024 before the open of the financial markets. About Virios Therapeutics Virios Therapeutics (NASDAQ:VIRI) is a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response such as fibromyalgia ("FM") and Long-CO